Frontiers in Pharmacology (Jan 2024)

GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs

  • Qingzhi Ji,
  • Huimin Zhu,
  • Yuting Qin,
  • Ruiya Zhang,
  • Lei Wang,
  • Erhao Zhang,
  • Xiaorong Zhou,
  • Run Meng

DOI
https://doi.org/10.3389/fphar.2024.1329636
Journal volume & issue
Vol. 15

Abstract

Read online

Albumin is derived from human or animal blood, and its ability to bind to a large number of endogenous or exogenous biomolecules makes it an ideal drug carrier. As a result, albumin-based drug delivery systems are increasingly being studied. With these in mind, detailed studies of the transport mechanism of albumin-based drug carriers are particularly important. As albumin receptors, glycoprotein 60 (GP60) and secreted protein acidic and rich in cysteine (SPARC) play a crucial role in the delivery of albumin-based drug carriers. GP60 is expressed on vascular endothelial cells and enables albumin to cross the vascular endothelial cell layer, and SPARC is overexpressed in many types of tumor cells, while it is minimally expressed in normal tissue cells. Thus, this review supplements existing articles by detailing the research history and specific biological functions of GP60 or SPARC and research advances in the delivery of antitumor drugs using albumin as a carrier. Meanwhile, the deficiencies and future perspectives in the study of the interaction of albumin with GP60 and SPARC are also pointed out.

Keywords